Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott acquires US rights to NexMed drug
NexMed submitted a new drug application with the FDA on September 21, 2007 and is awaiting confirmation of acceptance of its filing. Under the terms of the agreement,
NexMed submitted a new drug application with the FDA on September 21, 2007 and is awaiting confirmation of acceptance of its filing. Under the terms of the agreement,
The acquisition was funded with available cash and the proceeds from the company’s recent offering of convertible senior notes. Mario Molina, president and CEO of Molina Healthcare, said:
AVI is planning clinical development of AVI-4658 including a dose-ranging trial using systemic administration of the drug. This trial will be conducted in conjunction with the company’s duchenne
Ralivia has been shown to produce reductions in pain intensity relative to placebo as early as the first day of treatment, with analgesic efficacy increasing throughout the first
In this 12-week double-blind trial, 300 African-American patients with stage I-II hypertension were randomly assigned to receive once-daily placebo or nebivolol at a 2.5, 5, 10, 20, or
The shareholders of National Health Realty (NHR) have voted to approve the merger of NHR with a wholly-owned subsidiary of NHC. Following the meeting, the shareholders of National
The recently completed AM103 trial was designed to assess the safety and tolerability of an escalating single dose of the compound and escalating multiple doses in healthy volunteers
The primary efficacy endpoint of the trial was the change in six-minute walk (6MW) distance at 12 weeks measured at peak exposure, defined by the trial protocol as
With the cancellation of the listing on the London Stock Exchange, shareholders may deposit their ordinary shares with the company’s depositary bank, The Bank of New York, in
This patent, covering the measurement of HE4 and antibodies to HE4 in blood, serum and plasma, will allow Fujirebio Diagnostics to continue developing its biomarker for screening, detecting,